Recent Phase 1 studies have explored novel combinations, such as entrectinib, a neurotrophin receptor kinase (NTRK) inhibitor used in solid tumors, with oral decitabine and cedazuridine (ASTX727) in RR AML with TP53 mutations. Here, TP53 is linked to acute myeloid leukemia.